Estrogen receptor-negative breast cancer: new insights into subclassification and targeting.
Classification schemes for disease states can help identify distinctions with useful implications for therapy and prognosis. Speers and colleagues provide a new subclassification scheme for estrogen receptor-negative breast cancer based upon kinome-wide gene expression profiling with interesting findings that are potentially relevant for both treatment and clinical outcome.
Zhao
Jean J
JJ
Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.
Silver
Daniel P
DP
D001943:Breast Neoplasms / Q000145:classification* / Q000201:enzymology / Q000235:genetics / Q000378:metabolism*; D016503:Drug Delivery Systems; D005260:Female; D020869:Gene Expression Profiling; D006801:Humans; D009376:Neoplasms, Hormone-Dependent; D010770:Phosphotransferases / Q000378:metabolism; D011960:Receptors, Estrogen / Q000378:metabolism*; D015398:Signal Transduction
D011960:Receptors, Estrogen; D010770:Phosphotransferases